SSA
PGNX

Schonfeld Strategic Advisors’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Schonfeld Strategic Advisors’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-37,918
Closed -$159K – 1411
2018
Q4 		$159K Buy
+37,918
New +$193K 0.01% 975
2016
Q4 		– Sell
-15,374
Closed -$97K – 685
2016
Q3 		$97K Buy
+15,374
New +$92.9K 0.02% 393

Other funds holding PGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Schonfeld Strategic Advisors's PGNX Position: Q1 2019 in Review

Schonfeld Strategic Advisors sold out of Progenics Pharmaceuticals Inc (PGNX) in Q1 2019, closing a stake of 37,918 shares — an estimated $159K sold.

Schonfeld Strategic Advisors first reported a position in PGNX in Q3 2016 and held it in 2 quarters. The position peaked at $159K in Q4 2018. 148 funds tracked by Wall St. Rank hold PGNX as of Q1 2019.

  • Schonfeld Strategic Advisors reported no remaining Progenics Pharmaceuticals Inc position as of Q1 2019 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 37,918 Progenics Pharmaceuticals Inc shares in Q1 2019, an estimated $159K.
  • Schonfeld Strategic Advisors first reported a position in Progenics Pharmaceuticals Inc in Q3 2016 and held it in 2 quarters.
  • Schonfeld Strategic Advisors's Progenics Pharmaceuticals Inc position peaked at $159K in Q4 2018.
  • 148 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q1 2019.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2019, filed 15 May 2019.